What Is Retatrutide?
Retatrutide (LY3437943, also known as GGG tri-agonist) is a synthetic peptide developed by Eli Lilly currently in Phase 3 clinical development. Unlike dual GIP/GLP-1 agonists (Tirzepatide), Retatrutide adds a third mechanism of action: glucagon receptor agonism. This triple receptor profile has generated significant research interest, with Phase 2 data published in the New England Journal of Medicine (2023) reporting mean body weight reductions of 17.5% at 24 weeks and 24.2% at 48 weeks at the highest dose tested.
For research teams already working with GLP-1 compounds, Retatrutide represents a next-generation triple agonist comparator. For researchers new to this class, our Retatrutide Research Overview covers mechanism of action, Phase 2/3 trial data, and comparison with Tirzepatide in detail.
This page focuses on procurement. The research overview covers the science. For research use only.
Retatrutide Products
Two concentrations available, supplied in boxes of 10 research-grade vials.
Why Researchers Choose Eternal Peptides
Janoshik-Verified Every Batch
HPLC purity, mass spectrometry identity, sterility (USP), endotoxin (LAL), and heavy metals (ICP-MS). Not occasional testing — every batch. COAs published on each product page before you order.
Australian-Owned and ABN Registered
Not an overseas supplier behind an Australian domain. Eternal Peptides Wholesale is an ABN-registered Australian business dispatching domestically. ABN shown on all invoices.
COAs Available Before Purchase
Every COA includes the Janoshik report number for independent verification at janoshik.com. You can review the testing data before placing an order — not only after.
Wholesale Box Pricing
Products are supplied in box quantities (10 vials per box). No per-vial markups. Pricing structure designed for research procurement budgets, not single-use retail.
About Janoshik Analytical Testing
Janoshik Analytical is an accredited third-party laboratory used widely by research peptide suppliers. Unlike in-house testing, third-party verification through Janoshik provides independent confirmation of identity and purity.
Each COA includes a unique report number. You can verify any COA independently by looking up the report number at janoshik.com. This removes any possibility of falsified documentation — if the COA is real, the verification check will pass.
For Retatrutide, the Janoshik testing panel covers HPLC purity analysis, mass spectrometry identity confirmation, sterility testing, endotoxin, and heavy metals. The full test results are published on the RT10 and RT20 product pages. For detailed information on what the testing methodology covers, see our guide to Janoshik testing.
Regulatory Context for GLP-1 Class Compounds in Australia
GLP-1 class compounds including Retatrutide, Tirzepatide, and Semaglutide have been subject to increased TGA regulatory attention following the October 2024 TGA compounding changes. Eternal Peptides Wholesale supplies these compounds for qualified laboratory research use only. They are not supplied for human therapeutic use, compounding for human administration, or any purpose outside qualified laboratory research. Customers are responsible for understanding and complying with all applicable Australian regulatory requirements for their specific research context. We recommend consulting your own legal and compliance advisors if you have questions about your obligations.
Frequently Asked Questions
Where can I buy Retatrutide in Australia? +
Eternal Peptides Wholesale is an Australian-owned ABN-registered distributor supplying Retatrutide for research purposes. RT10 (10mg, box of 10) is $544.50 and RT20 (20mg, box of 10) is $891.00. Every batch is Janoshik-verified with COAs published on each product page. Dispatched from Australia within 1-2 business days. For research use only.
What is the difference between RT10 and RT20? +
RT10 contains 10mg of Retatrutide per vial (box of 10 vials, $544.50). RT20 contains 20mg of Retatrutide per vial (box of 10 vials, $891.00). Both are supplied as boxes of 10 vials. Concentration selection depends on your research protocol. Both are independently verified by Janoshik Analytical with batch-specific COAs on each product page. For research use only.
How is the quality of Retatrutide verified? +
Every batch is independently tested by Janoshik Analytical, covering HPLC purity (identity and concentration), mass spectrometry identity confirmation, sterility (USP method), endotoxin (LAL assay), and heavy metals (ICP-MS). The COA for each batch is published on the product page and the Janoshik report number can be independently verified at janoshik.com before or after purchase. For research use only.
What is Retatrutide's mechanism of action? +
Retatrutide is a triple GIP, GLP-1, and glucagon receptor agonist. This triple mechanism distinguishes it from dual GIP/GLP-1 agonists like Tirzepatide. The glucagon receptor component contributes to energy expenditure effects that dual agonists do not capture. For full mechanism detail, Phase 2/3 trial data, and comparison with Tirzepatide, see the Retatrutide Research Overview. For research use only.
Is Retatrutide approved for human use in Australia? +
No. Retatrutide is currently in Phase 3 clinical development and is not approved by the TGA for therapeutic use in Australia. Eternal Peptides Wholesale supplies Retatrutide for qualified laboratory research use only. It is not for human therapeutic use or consumption. GLP-1 class compounds have been subject to increased TGA regulatory attention since October 2024. Customers should seek independent legal and compliance advice regarding their specific research context.
How long does shipping take? +
Orders are dispatched within 1-2 business days of payment confirmation. Retatrutide ships from Australia domestically. Certificates of Analysis are included with every order. Contact us before ordering if your protocol has specific temperature or logistics requirements.